Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Grants Breakthrough Device Designation to Serial CTRS AI Model for NSCLC

February 7th 2025

The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.

Northwestern Medicine Performs the Highest Number of Lung Transplants in the United States

February 7th 2025

The Canning Thoracic Institute became the highest-volume lung transplant center in the US and achieved the shortest wait time for a lung transplant.

Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC

February 6th 2025

Tina Cascone, MD, PhD, discusses the efficacy and safety of neoadjuvant durvalumab plus novel agents or chemotherapy in resectable NSCLC.

FDA Grants Orphan Drug Designation to 225Ac-Satoreotide for SCLC

February 6th 2025

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer

February 5th 2025

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

Serplulimab Plus Chemotherapy Wins EU Approval for Treatment-Naive ES-SCLC

February 5th 2025

The European Commission has approved serplulimab in combination with carboplatin and etoposide for the frontline treatment of adult patients with ES-SCLC.

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors

February 5th 2025

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

February 4th 2025

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

THIO Plus Cemiplimab Demonstrates Potential OS Benefit in Pretreated Advanced NSCLC

February 4th 2025

THIO plus cemiplimab generated a potential survival benefit in pretreated advanced non–small cell lung cancer.

Subcutaneous Amivantamab Nears EU Approval in Advanced EGFR+ NSCLC

February 4th 2025

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC

February 3rd 2025

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

CHMP Recommends Approval of Durvalumab for Limited-Stage Small Cell Lung Cancer

February 3rd 2025

The CHMP has recommended approval for durvalumab in limited-stage small cell lung cancer following platinum-based chemoradiation.

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

February 2nd 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research

February 2nd 2025

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

February 2nd 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

February 2nd 2025

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy

February 2nd 2025

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer

February 1st 2025

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

February 1st 2025

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.